Want to see FHTX full AI Analyst Report?
FHTX Stock Chart & Stats
$4.85
$0.35(7.22%)
At close: 4:00 PM EDT
$4.85
$0.35(7.22%)
Day’s Range― - ―
52-Week Range$3.27 - $6.95
Previous Close$5.36
Volume159.32K
Average Volume (3M)157.41K
Market Cap
$400.26M
Enterprise Value$220.19
Total Cash (Recent Filing)$167.58M
Total Debt (Recent Filing)$43.10M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
Nov 10, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding59,385,315
10 Day Avg. Volume207,613
30 Day Avg. Volume157,412
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.00Price Target Upside147.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$32.20M
Bulls Say, Bears Say
Bulls Say
Strategic CollaborationA collaboration with Eli Lilly signals external validation and provides strategic resources. Over the medium term this can supply non-dilutive funding, clinical development support and commercialization expertise, improving odds of advancing programs to regulatory and commercial milestones.
Cash RunwayHaving ~$168M in cash and investments with runway into H1 2028 materially reduces near-term financing pressure. This gives management time to progress clinical programs toward inflection points, pursue selective partnerships, and avoid hurried dilutive financings over the next 12–18 months.
Diverse Pipeline ProgressProgress across multiple first-in-class chromatin-targeting programs, an active SMARCA2 trial and a 2027 IND target diversify the company’s clinical risk. Multiple catalysts across indications improve the chance of at least one successful program driving durable value creation and strategic partnerships.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow near -$84M annually creates ongoing funding needs. Over months, this increases dependence on external capital or collaborations, risks dilution or unfavorable financing terms, and constrains discretionary R&D or expansion if cash falls faster than planned.
Negative Equity & LeverageNegative shareholders' equity combined with meaningful debt reduces balance-sheet flexibility and raises refinancing risk. Structurally, this increases the cost of capital, limits ability to absorb setbacks, and may force reliance on dilutive financing or restrictive partnership terms to fund development.
Large Losses & Margin PressureDeep ongoing net losses and a sharply negative net margin, plus deteriorating gross profit, indicate the business is not generating durable operating profits. Long-term sustainability depends on clinical success or material revenue shifts; absent that, profitability and margin recovery remain uncertain.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $3.27 and its highest was $6.95 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $400.26M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 83 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.145.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.24.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 59,385,315 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went up 14.139%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (147.42% Upside)
$12.00 (147.42% Upside)
Blogger Sentiment
Bullish
FHTX Sentiment 100%
Sector Average 61%
Sector Average 61%
Hedge Fund Trend
Increased
By 904.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 2.6%
Last 30 Days ▼ 3.4%
Last 30 Days ▼ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-10.10%
Trailing 12-Months
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$12.00
▲(147.42% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Fulcrum Therapeutics
―
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
C4 Therapeutics
―
Ownership Overview
1.09% Insiders
10.37% Mutual Funds
46.15% Other Institutional Investors
36.24% Public Companies and
Individual Investors